Longevity News
The latest longevity research, curated from leading sources and analyzed through the EDGE Framework.
The latest longevity research, curated from leading sources and analyzed through the EDGE Framework.
Five patients with end-stage kidney disease received genetically engineered pig kidneys through an expanded access program, with three maintaining kidney function for over eight months without dialysis and two subsequently transitioning to human donor kidneys. This represents the first documented cases of xenotransplantation functioning as genuine bridge therapy, extending dialysis-free survival while preserving access to human organ transplantation.
Venus Healthcare Homes is exporting its integrated care-village model to Malaysia and across ASEAN, where demographic aging is compressing into a single decade—a timeline that demands infrastructure built for population-wide health maintenance rather than crisis management. The model positions healthy aging as an economic asset only when care systems reach beyond affluent populations to keep ordinary older people well and community-connected.
Function Health has launched a secure connector allowing users to feed personalized lab results and clinical notes into mainstream AI chatbots—ChatGPT, Claude, and Perplexity—enabling AI to provide answers grounded in individual biomarkers rather than population averages. This addresses a critical gap: AI health guidance has been generic and contextless, while over 80% of Function's members show at least one biomarker outside optimal ranges that warrant investigation and intervention.
HCW Biologics secured U.S. patent protection for HCW9302, an IL-2-based immunotherapeutic designed to expand regulatory T cells in alopecia areata. Early Phase 1 data show positive responses after single-dose treatment with no dose-limiting toxicities, positioning the candidate for continued development through 2026.
Scribe Therapeutics has initiated human trials of STX-1150, a gene therapy designed to silence PCSK9 and reduce LDL cholesterol. Preclinical data in primates demonstrated sustained LDL reductions exceeding 50% at therapeutic doses, with potential implications for cardiovascular risk reduction in patients with familial hypercholesterolemia or statin-resistant disease.
Rapalogix Health established a dedicated research laboratory at Princeton Innovation Center to advance translational research on rapalogs, proprietary compounds designed to modulate longevity pathways in skin. The facility enables systematic investigation of mechanism of action, formulation optimization, and biomarker development for next-generation skin longevity products.
China's regulatory approval of lecanemab's subcutaneous formulation expands access to an amyloid-targeting monoclonal antibody for early Alzheimer's disease. The weekly self-injection regimen reduces treatment burden compared to intravenous administration, potentially increasing uptake among the estimated 17 million Chinese patients with mild cognitive impairment or mild dementia.
FibroBiologics received a U.S. patent for a topical wound therapy using 3D fibroblast spheroids and fibroblast-derived materials, with preclinical evidence showing accelerated healing in diabetic and non-diabetic wound models. This approach addresses chronic wounds—a significant driver of morbidity and cost—by leveraging the regenerative capacity of fibroblast-derived signaling molecules rather than the cells themselves.
Mito Health, a direct-to-consumer diagnostics platform, has administered over one million tests across seven preventive categories including genomic sequencing, microbiome analysis, advanced imaging, and liquid biopsy screening. The expansion reflects growing demand for accessible, transparent-pricing diagnostic services that operate outside traditional insurance infrastructure.
Insilico Medicine, an AI-driven drug discovery company, achieved inclusion in the HKEX Tech 100 Index and reported its first profitable half-year since listing, with 287% revenue growth and $11 billion in cumulative contract value. This milestone reflects commercial validation of computational approaches to accelerating drug development timelines.
Aging compromises the brain's ability to flexibly coordinate posture and balance through a paradoxical mechanism: central neural networks become overly rigid while peripheral sensory input becomes disconnected from motor control. This fundamental loss of adaptive capacity directly undermines fall prevention and movement quality across the lifespan.
Tim Maupin's film explores the ethical and personal dimensions of rejuvenation technology arriving before universal access, examining what happens when life-extension therapies can save some but not others. The narrative anchors longevity science in the lived human experience of aging parents and the institutional barriers that determine who benefits from breakthrough interventions.